Suppr超能文献

使用原微小RNA-17∼92适体阻断视网膜母细胞瘤中致癌微小RNA的成熟

Blocking the maturation of OncomiRNAs using pri-miRNA-17∼92 aptamer in retinoblastoma.

作者信息

Subramanian Nithya, Kanwar Jagat R, Kanwar Rupinder K, Krishnakumar Subramanian

机构信息

1 Department of Nanobiotechnology, Vision Research Foundation, Kamalnayan Bajaj Institute for Research in Vision and Ophthalmology , Chennai, India .

出版信息

Nucleic Acid Ther. 2015 Feb;25(1):47-52. doi: 10.1089/nat.2014.0507. Epub 2014 Dec 16.

Abstract

The miR-17∼92. or oncomiR-1, cluster encodes oncogenic microRNAs (miRNAs), and it also promotes retinoblastoma (RB) tumor formation. Antagomir and miRNA mimics based approaches are widely tried against oncogenic and tumor suppressive miRNAs. Other methods for targeting cancer related miRNAs are still under development. In the current study, we focused on the pri-miRNA-17∼92 aptamer (pri-apt), which can potentially replace the mix of five antagomirs by one aptamer that function to abrogate the maturation of miR-17, miR-18a, and miR-19b (P<0.05) for targeting RB. We used RB cell lines WERI-Rb1 and Y79 as an in vitro model. Cellular changes upon transfecting the pri-apt led to S-phase arrest in WERI-Rb1 cells and onset of apoptosis in both Y79 and WERI-Rb1 cell lines. There was increased cytotoxicity as measured by lactate dehydrogenase activity in pri-apt treated Y79 cells (P<0.05), and significant inhibition of cell proliferation was observed in both of the cell lines. Thus we showed the antiproliferative property of pri-apt in RB cell lines, which can be readily modified by developing appropriate vectors for the delivery of the aptamer specifically to cancer cells.

摘要

miR-17∼92(又称致癌miR-1)簇编码致癌性微小RNA(miRNA),它还能促进视网膜母细胞瘤(RB)的肿瘤形成。基于抗miR和miRNA模拟物的方法被广泛用于对抗致癌性和肿瘤抑制性miRNA。其他靶向癌症相关miRNA的方法仍在研发中。在本研究中,我们聚焦于初级miRNA-17∼92适配体(pri-apt),它有可能用一种适配体替代五种抗miR的混合物,该适配体的作用是消除miR-17、miR-18a和miR-19b的成熟(P<0.05)以靶向RB。我们使用RB细胞系WERI-Rb1和Y79作为体外模型。转染pri-apt后细胞发生的变化导致WERI-Rb1细胞停滞于S期,Y79和WERI-Rb1细胞系均出现凋亡。pri-apt处理的Y79细胞中,通过乳酸脱氢酶活性测定的细胞毒性增加(P<0.05),并且在这两种细胞系中均观察到细胞增殖受到显著抑制。因此,我们展示了pri-apt在RB细胞系中的抗增殖特性,通过开发合适的载体将适配体特异性递送至癌细胞,该特性可以很容易地被修饰。

相似文献

引用本文的文献

1
4
miRNAs in Cancer (Review of Literature).miRNAs 在癌症中的作用(文献综述)。
Int J Mol Sci. 2022 Mar 3;23(5):2805. doi: 10.3390/ijms23052805.
5
Non-Coding RNAs in Retinoblastoma.视网膜母细胞瘤中的非编码RNA
Front Genet. 2019 Nov 14;10:1155. doi: 10.3389/fgene.2019.01155. eCollection 2019.
6
Expression profiles and prognostic value of miRNAs in retinoblastoma.miRNAs 在视网膜母细胞瘤中的表达谱及预后价值。
J Cancer Res Clin Oncol. 2019 Jan;145(1):1-10. doi: 10.1007/s00432-018-2773-7. Epub 2018 Oct 22.
9
Epigenetic regulation of human retinoblastoma.人类视网膜母细胞瘤的表观遗传调控
Tumour Biol. 2016 Nov;37(11):14427-14441. doi: 10.1007/s13277-016-5308-3. Epub 2016 Sep 17.

本文引用的文献

1
The genomic landscape of retinoblastoma: a review.视网膜母细胞瘤的基因组全景:综述。
Clin Exp Ophthalmol. 2014 Jan-Feb;42(1):33-52. doi: 10.1111/ceo.12132. Epub 2013 May 22.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验